Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

NCT07587827 | Not Yet Recruiting Phase 1 DMC

• 1 other identifier: 2025-523172-23-00
• Study Type: interventional
• Target: 77
• Locations: 1 country
• Sites: 2

Brief Summary

This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab), in patients with metastatic or locally advanced colorectal or pancreatic cancer. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) followed by an expansion phase to evaluate efficacy in terms of progression-free survival

Conditions

Locally Advanced Colorectal Cancer; Metastatic Pancreatic Cancer; Locally Advanced Pancreatic Cancer; Metastatic Colorectal Cancer (CRC)

Keywords

vaccine; pancreas; colorectal; phase 1

Outcome Measures

Primary Outcomes (1)

• Phase 1 : Maximum Tolerated Dose (MTD) based on Dose Limiting Toxicity (DLT) (28 days) of ODI-2001 Phase 2 : Progression-Free Survival (PFS)

  Phase 1 : The maximum tolerated Dose (MTD) is defined as the highest dose level of ipilimumab in comination with the ODI-2001 vaccine at which no more than 1 out of 6 patients experiences a dose Limiting Toxicities (DLT). DLT are assessed according to NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 5.0 and include predefined hematologic and non-hematologic toxicities considerad related to ODI-2001 administration. If ≥ 2 patients in a cohort of up to 6 patients experience a DLT, the dose is considered above the MTD. Phase 2 : Progression-Free Survival (PFS) is defined as the time from the start of first-line chemotherapy to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method.

  Phase 1 : within 28 days following the first administration of ODI-2001 Phase 2 : Up to 14 months for colorectal cancer cohort and up to 10 months for pancreatic cancer cohort following initiation of chemotherapy.

Study Arms (3)

Level 1 - Ipilimumab (Anti-CTLA4): 2.5 mg

EXPERIMENTAL

Participants recevront la dose de départ : DNA vaccine 4 mg, MVA 10⁷ pfu, Ipilimumab 2.5 mg (Anti-CTLA4). This arm may be expanded in Phase II if dose is selected as RP2D (Recommended Phase 2 Dose)

Biological: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)

Level 2 - Ipilimumab 5 mg

EXPERIMENTAL

Participants recevront DNA vaccine 4 mg, MVA 10⁷ pfu, Ipilimumab 5 mg (Anti-CTLA4).This arm may be expanded in Phase II if dose is selected as RP2D (Recommended Phase 2 Dose)

Biological: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)

Level 3 - Ipilimumab 10 mg

EXPERIMENTAL

Participants recevront DNA vaccine 4 mg, MVA 10⁷ pfu, Ipilimumab 10 mg (Anti-CTLA4). This arm may be expanded in Phase II if dose is selected as RP2D (Recommended Phase 2 Dose)

Biological: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)

Interventions

Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4) BIOLOGICAL

Participants receive a combination therapy including DNA vaccine 4 mg IM, MVA 10⁷ pfu, and Ipilimumab IV at the dose assigned per arm: 2.5 mg, 5 mg, or 10 mg. Dose escalation is done sequentially in Phase I. The selected dose (RP2D) will be used in Phase II expansion.

Level 1 - Ipilimumab (Anti-CTLA4): 2.5 mg; Level 2 - Ipilimumab 5 mg; Level 3 - Ipilimumab 10 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Male or female of \> 18 years of age
• Histologically confirmed diagnosis of metastatic or locally advanced solid tumour: • Colorectal carcinoma with MicroSatellite Stable colorectal carcinoma (MSS) not eligible for surgery or other ablative therapies. • Pancreatic adenocarcinoma not eligible for surgery or other ablative therapies.
• ECOG performance status 0 or 1
• Baseline Tumoral evaluation (thoraco-abdomino-pelvic computed tomography) performed before the initiation of the standard first line-chemotherapy with at least one measurable lesion according to RECIST 1.1 criteria that can be accurately assessed at baseline and is suitable for repeated assessment.
• Eligible to start a standard first line chemotherapy indicated in colorectal cancer (FOLFOX/FOLFIRI/FOLFIRINOX or FOLFOXIRI +/- anti-VEGF/EGF) pancreatic cancer (FOLFIRINOX/NabPaclitaxel-Gemcitabine).
• Adequate haematological, renal and hepatic laboratory requirements : • Haemoglobin \> 9.0 g/dL • White Blood Cells (WBC) \> 2.5x109/L including, absolute neutrophils count (ANC) \> 1.5x109/L, total lymphocytes count \> 0.5x109/L • Platelet's count \> 100x109/L• Serum alkaline phosphatase (PAL) ≤ 3 x ULN in the absence of liver or bone metastases and ≤ 5 x ULN in patients with documented bone or liver metastases• Serum transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN in the absence of liver metastases and ≤ 5 x ULN in case of liver metastases
• Total bilirubin ≤ 1.5 x ULN• Albumin ≥ 30 g/L • Glomerular Filtration Rate ≥ 50 mL/min (according to Modification of the Diet in Renal Disease \[MDRD\] formula or Cockroft \& Gault formula)
• Adequate cardiac function with QTc \< 450 msec on baseline ECG, using the Fridericia correction cQTcF formula
• Life expectancy of at least 6 months
• Patient willing and able to comply with scheduled visits and exams during the follow-up and treatment compliance of the protocol, for the duration of the study including : • mandatory blood sampling (3 blood sampling) • mandatory biopsy of the tumor following enrolment in STEP 1 if no archived material dated less than 2 years is available in sufficient quality or quantity and a mandatory biopsy at 2 months after the initiation of ODI-2001 vaccine administration.
• Men who are sexually active with women of childbearing potential must agree to use contraceptive method during the ODI-2001 treatment period and for at least 4 months after the last ODI-2001 administration. The individual methods of contraception may be determined in consultation with the investigator and it must have a failure rate of less than 1% per year.
• A female participant is eligible to participate if she is not pregnant (negative urinary or serum pregnancy test), not breastfeeding, and at least one of the following conditions applies: • Not a woman of childbearing potential OR • Women of childbearing potential who agrees to apply effective contraception method during the treatment period and for at least 4 months after the last dose of study treatment. Effective contraception methods include a combination of any of the following (unless method is abstinence or sterilization, in which only one method is required): - Use of oral, injected, or implanted hormonal methods of contraception, or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%). In case of use of oral contraception, women should have been stable on the same pill for a minimum of 6 months before taking study treatment. - Placement of an intrauterine device or intrauterine system. - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository. - Total abstinence - Female sterilization at least eight weeks before taking study treatment. - Male sterilization (at least six months prior to screening)
• Patient must be affiliated to a social health insurance regimen
• First tumoral evaluation shows disease response with the following definition:

You may not qualify if:

• Patients with \>10% hepatic involvement as per investigator
• Exposure to any investigational agent within 30 days of enrolment.
• Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
• History of any second malignancy within 2 years with the exception of malignancies with a negligible risk of metastasis or death (e.g. adequately treated carcinoma-in situ of the breast or the cervix, melanoma-in-situ, prostate cancer with Gleason grade ≤6 and prostate specific antigen within normal range).
• Known or suspected history of immunosuppression (severe auto-immune or immunodeficiency disease) including history of invasive opportunistic infections (e.g tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis, aspergillosis) despite infection resolution. Presence or suspicion of active bacterial, fungal or viral infections, or uncontrolled fever
• Patients with major surgery within 4 weeks from enrolment
• Previous vaccination (either therapeutic and/or prophylactic) against cancer
• Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) unless used at dose levels that are not immunosuppressive (e.g. Prednisone at 10 mg/day or less or as inhaled steroid at doses used for the treatment of asthma) up to 14 days before pre-enrolment.
• Is receiving growth factors including, but not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, etc. within 4 weeks from enrolment
• Known history of Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence of HBs antigen in the serum
• History of severe auto-immune or immunodeficiency disease
• Known allergy to any of the components of ODI-2001 (e.g. egg or gentamycin)
• Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
• Planned to receive yellow fever or other live (attenuated) vaccines during the course of the study
• Recent or active clinically significant infection requiring therapy at the time of first dose

Sponsors & Collaborators

• Centre Georges Francois Leclerc: lead

Study Sites (2)

CHRU Jean Minjoz

Besançon, 25000, France

Location

Centre Georges-François Leclerc

Dijon, 21000, France

Location

MeSH Terms

Conditions

Colorectal Neoplasms; Pancreatic Neoplasms

Interventions

Ipilimumab

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Jean-Marc JML LIMACHER, Dr

  Odimma Therapeutics

  STUDY CHAIR

Central Study Contacts

François FG GHIRINGHELLI, Pr

CONTACT

03 45 34 75 38; fghiringhelli@cgfl.fr

Emilie ER REDERSTORFF, Project Manager

CONTACT

03 45 34 81 16; erederstorff@cgfl.fr

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: First : Dose escalation And then, Expansion phase

Study Record Dates

• First Submitted: May 4, 2026
• First Posted: May 14, 2026
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2031
• Last Updated: May 14, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2)